- Home
- JWEL vs CYCC Comparison
JWEL vs CYCC Comparison
Compare JWEL & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- CYCC
- Stock Information
- Founded
- JWEL 2012
- CYCC 1992
- Country
- JWEL China
- CYCC Malaysia
- Employees
- JWEL N/A
- CYCC N/A
- Industry
- JWEL Other Consumer Services
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- CYCC Health Care
- Exchange
- JWEL Nasdaq
- CYCC Nasdaq
- Market Cap
- JWEL 3.9M
- CYCC 3.6M
- IPO Year
- JWEL 2021
- CYCC N/A
- Fundamental
- Price
- JWEL $1.71
- CYCC $0.23
- Analyst Decision
- JWEL
- CYCC Strong Buy
- Analyst Count
- JWEL 0
- CYCC 1
- Target Price
- JWEL N/A
- CYCC $11.00
- AVG Volume (30 Days)
- JWEL 4.0K
- CYCC 179.7K
- Earning Date
- JWEL 05-12-2025
- CYCC 05-13-2025
- Dividend Yield
- JWEL N/A
- CYCC N/A
- EPS Growth
- JWEL N/A
- CYCC N/A
- EPS
- JWEL N/A
- CYCC N/A
- Revenue
- JWEL $160,009,293.00
- CYCC $43,000.00
- Revenue This Year
- JWEL N/A
- CYCC $137.21
- Revenue Next Year
- JWEL N/A
- CYCC N/A
- P/E Ratio
- JWEL N/A
- CYCC N/A
- Revenue Growth
- JWEL N/A
- CYCC N/A
- 52 Week Low
- JWEL $1.00
- CYCC $0.17
- 52 Week High
- JWEL $3.71
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- JWEL 31.74
- CYCC 41.57
- Support Level
- JWEL $1.77
- CYCC $0.17
- Resistance Level
- JWEL $2.14
- CYCC $0.32
- Average True Range (ATR)
- JWEL 0.13
- CYCC 0.03
- MACD
- JWEL 0.01
- CYCC 0.00
- Stochastic Oscillator
- JWEL 7.53
- CYCC 46.15
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.